There is debate regarding the correlation between in vitro susceptibility testing and clinical response to therapy for bacteroides bacteremia. We conducted a prospective multicenter observational study of 128 patients with bacteroides bacteremia. Outcome was correlated with results of in vitro susceptibility testing of Bacteroides isolates recovered from blood and/or nonblood sites, determined with use of 3 end points: mortality at 30 days, clinical response (cure vs. failure), and microbiological response (eradication vs. persistence). The mortality rate among patients who received inactive therapy (45%) was higher than among patients who received active therapy (16%;
Unlike susceptibility testing of aerobic bacteria, which has been useful for selecting optimal antimicrobial therapy, susceptibility testing of anaerobic bacteria has not been generally used for clinical decision making because of a number of limitations, such as the slow growth of organisms, the polymicrobial nature of anaerobic infections, the complexity of the testing method, the lack of consensus regarding the optimal media to be used in testing, and the general concept that susceptibility patterns among the anaerobes are predictable and have remained unchanged over the years [1] [2] [3] [4] . There have been limited data correlating in vitro susceptibility results with outcomes [2, 5] . Such correlation is difficult to determine, given the nature of anaerobic infections, in which the final outcome depends on a constellation of factors, including the source of infection, the coexistence of other pathogens, and the need for surgical drainage.
Over the past 5 years, a significant decline has been reported in the in vitro activity of some antianaerobic agents (such as clindamycin and b-lactams) against Bacteroides, the most important anaerobic pathogen [6] . Whether this in vitro trend translates into clinical failure is not known. We undertook a multicenter prospective study of bacteroides bacteremia to assess how well in vitro susceptibility predicts outcome.
Methods
We performed a prospective observational multicenter study of bacteremia due to Bacteroides species at 3 university tertiary care centers: Duke Medical Center (Durham, NC), New England Medical Center (Boston), and University of Pittsburgh Medical Center (Presbyterian University Hospital, Montefiore University Hospital, and Veterans Affairs Medical Center, Pittsburgh). The study lasted ∼3 years at each hospital and was conducted from January 1991 through May 1995.
Consecutive patients who had Bacteroides isolated from у1 blood culture were followed prospectively for 30 days or until their discharge from the hospital. Subsequent blood culture specimens were drawn at the discretion of attending physicians. All management decisions were made by the attending physicians, without intervention by the investigators.
Susceptibility Testing
Bacteria. Isolates associated with bacteroides bacteremia were collected by 3 medical centers participating in the study and were forwarded to the central laboratory at the New England Medical Center for susceptibility testing. Isolates were shipped on anaerobic agar slants (chopped meat agar; Carr Scarborough Microbiologicals, Stone Mountain, GA) and were stored in shipping media until the time of testing. Identification of all organisms was confirmed by retesting at the central laboratory at the time of antimicrobial susceptibility testing by means of standard methodology, as outlined in [7] and [8] .
Antimicrobial agents. Standard powders were obtained from the following companies: imipenem and cefoxitin (Merck, West Point, PA); ampicillin and sulbactam (Pfizer, NY); ticarcillin/clavulanic acid (SmithKline Beecham Laboratories, Bristol, TN); piperacillin (Lederle Laboratories, Pearl River, NY); cefotetan (Zeneca Pharmaceuticals, Wilmington, DE); clindamycin (Upjohn, Kalamazoo, MI); and metronidazole (Sigma Chemical, St. Louis).
The antimicrobials were prepared at 20 times the concentration desired and were kept frozen at Ϫ70ЊC until the day of use. The range of antibiotics tested was as follows: cefoxitin, 0.25-128 mg/mL; cefotetan, 0.25-256 mg/mL; ticarcillin, piperacillin, and ampicillin, 0.25 mg/mL to 128 g/mL; ticarcillin/clavulanate, piperacillin, and ampicillin/sulbactam, 0.25-128 mg/mL; clindamycin, 0.25-128 mg/mL; and imipenem, 0.125-8 mg/mL. Metronidazole was tested at 2 concentrations only: 1 mg/mL and 8 mg/mL. For the b-lactamase inhibitor clavulanate and for tazobactam, a constant amount of clavulanic acid (2 mg/mL) was combined with serial 2-fold dilutions of ticarcillin. For sulbactam, we tested a fixed 2 : 1 ratio of serial 2-fold dilutions of ampicillin combined with sulbactam.
Susceptibility tests. The susceptibility of the bloodstream Bacteroides isolates was determined by a modified agar dilution method with use of brain-heart infusion agar (BBL; Becton Dickinson, Cockeysville, MD) supplemented with 5% lysed sheep RBCs and 0.005% vitamin K 1 . The isolates were subcultured twice on anaerobic blood agar (PML Microbiologicals, Tualatin, OR) before testing. The antibiotic-containing plates were prepared in-house on the day of the test by adding serial 2-fold dilutions of the corresponding antibiotics to molten agar. The bacteria were grown to logarithmic phase in brain-heart infusion-supplemented broth (BHIS; Carr Scarborough Microbiologicals) and were diluted with BHIS to ∼10 7 cfu/mL.
A Steers replicator (Atlantic Metalworks, Fairlawn, NJ) was used to deliver the inocula (10 4 cfu/spot) onto the surface of the agar plates. The plates were incubated at 37ЊC for 48 h in an anaerobic chamber (Coy, Grand Lake, MI) with an atmosphere of 10% H 2 , 10% CO 2 , and 80% N 2 .
The MIC was defined as the lowest concentration of antibacterial agent that inhibited visible growth. The susceptibility breakpoints employed were based on the recommendations of the Subcommittee on Antimicrobial Susceptibility Testing of the National Committee for Clinical Laboratory Standards (NCCLS) at the time of the study [9] .
Controls. Bacteroides fragilis ATCC 25285 and Bacteroides thetaiotaomicron ATCC 29741 were used as controls. Isolates were batched and run throughout the calendar year. All runs in which controls were beyond the limits specified by the NCCLS were rerun. Reading of the plates was done by the same set of technologists throughout the study.
Data and statistical analysis. Data were stored, retrieved, and analyzed by use of Lotus 1-2-3 (Lotus Development, Cambridge, MA).
Definitions
Therapy was defined as active if it included an antimicrobial agent to which the Bacteroides blood isolate was susceptible in vitro; such therapy must have been given for at least 3 days and within 7 days of a positive blood culture result. Therapy was defined as inactive if the blood isolate was resistant to all the antimicrobials used and if such therapy was given for at least 3 days and within 7 days of the onset of bacteremia.
Early therapy was defined as antimicrobial therapy with an active agent that was started within the first 2 days of bacteremia. Late therapy was defined as antimicrobial therapy with an active agent that was started 12 days after onset of bacteremia. Both early and late therapy had to be given for at least 3 days for inclusion in this study.
Combination therapy was defined as antimicrobial therapy with at least 2 active agents. Single therapy was defined as antimicrobial therapy with only 1 active agent. Both combination and single therapy had to be given for at least 3 days, within 7 days of onset of bacteremia.
Analytical Framework
Three end points were assessed: mortality, clinical response, and microbiological response. All analyses of patients were performed by investigators, without knowledge of in vitro susceptibility results. Mortality was recorded at 14 and 30 days after the initial positive blood culture results. Patients discharged from the hospital before 14 days were considered to have survived.
Clinical response. The criteria for assessment of clinical response (cure vs. failure) were based on the 1992 Infectious Diseases Society of America/US Food and Drug Administration guidelines for the evaluation of anti-infective drug products, with minor modifications [10] . Patients were considered to be clinically cured if the course of antimicrobial therapy and the initial surgical intervention (in cases of intra-abdominal infection or abscesses) resolved the infectious process and no early or late wound infections occurred.
Treatment was considered to be a clinical failure if (1) signs and symptoms of infections persisted despite at least 5 days of therapy, (2) additional operative procedures were required, (3) the initial therapy was altered because of persistence of signs or symptoms of infection, or (4) infections recurred after the therapy had been discontinued (relapse). Patients were considered to be nonevaluable if the initial surgical procedure was considered inadequate or if the patients received antimicrobial therapy for !3 days. The clinical end point for this study was based on the response to initial therapy.
Microbiological response. The microbiological response was classified as microbiological eradication or microbiological persistence. The response was considered to be microbiological eradication if (1) subsequent cultures after 3 days of therapy did not yield Bacteroides or (2) patients responded clinically and no subsequent cultures were performed. The response was considered to be microbiological persistence if any of the following criteria were fulfilled: (1) bacteroides bacteremia recurred despite antimicrobial therapy after an interval of 3 days or (2) Bacteroides persisted in blood or a nonblood site despite 3 days of such therapy. Patients who died within 7 days of onset of bacteremia and did not have any follow-up cultures performed before death were considered unevaluable.
Previous antianaerobic therapy. Previous antianaerobic therapy was defined as receipt of an antimicrobial agent with anaerobic activity for at least 2 days within the 14 days preceding onset of 
Statistical Analysis
Statistical analysis was performed on the PROPHET system (BBN Systems and Technologies, Cambridge, MA). Univariate analysis of contingency data was done by the 2-tailed x 2 or 2-tailed Fisher's exact test. Multivariate analysis of mortality risk factors was conducted by use of a logistic regression method. Factors included in the regression models were those found to be significant by univariate analysis at . P ! .05
Results

Demographics and underlying diseases.
One hundred twenty-eight patients with bacteroides bacteremia were enrolled over the 4-year study period (table 1). The median age of the patients was 61 years (range, 3 days to 88 years). Fifty-nine percent of the patients were male. Forty-four percent (56/128) underwent a surgical procedure within 4 weeks of the bacteremia, and 30% (38/128) had a malignancy. Forty-six percent (59/128) were critically ill at the onset of bacteremia (APACHE [acute physiology and chronic health evaluation] II score 115 or Pitt bacteremia score у4) [11] . Sixty percent of the patients developed bacteremia after 2 days of hospitalization, and the median duration of hospitalization before the development of bacteremia was 10 days (range, 3-109 days).
Microbiology. One hundred thirty-seven Bacteroides isolates were recovered from the blood of 128 patients. Nine patients were infected with 2 different Bacteroides species. The Bacteroides species recovered were B. fragilis (55%), B. thetaiotaomicron (20%), B. caccae (7%), B. uniformis (6%), B. vulgatus (6%), B. distasonis (4%), B. ovatus (4%), and B. ureolyticus (1%).
All Bacteroides isolates recovered from blood were subjected to in vitro antimicrobial susceptibility testing. None of the isolates were resistant to imipenem or metronidazole. Non-B. fragilis isolates were significantly more likely to be resistant to cefotetan (73%) than were B. fragilis isolates (27%;
). P ! .001 Otherwise, there was no significant difference between the B. fragilis and non-B. fragilis isolates in terms of the rates of resistance to other agents. All 11 isolates resistant to cefoxitin were resistant to ticarcillin ( ), cefotetan ( ), and P ! .001 P ! .001 piperacillin ( ); only 2 (18%) of 11 were resistant to P ! .001 clindamycin. Thirty-one (70%) of the 44 isolates resistant to piperacillin were resistant to cefotetan ( ), and 43 (97%) P ! .001 of the 44 were resistant to ticarcillin ( ); only 9 (20%) P ! .001 of the 44 were resistant in vitro to clindamycin.
Therapy and outcome. Thirty-six patients were excluded from the therapeutic analysis for the following reasons: death within 3 days of onset of bacteremia (15 patients), lack of surgical drainage for abscesses or repair of primary process (4), receipt of treatment with surgical intervention alone (1), or !3 days of therapy within 7 days of the blood culture positivity (11). In addition, 5 patients had "transient" bacteremia shortly after an invasive procedure. One received bactrim; the others received no therapy and were discharged. These patients were excluded. Of the remaining 92 patients for whom therapy could be evaluated, 81 were treated with an antimicrobial agent to which the isolate was susceptible, and 11 were treated with an agent to which the isolate was resistant. Forty-one patients underwent surgery as part of therapy for bacteremia: 26 (70%) of 37 with an intra-abdominal source of infection and 15 (34%) of 44 without an intra-abdominal source ( ). P = .002 Mortality. The mortality rates at 14 and 30 days were 16% (15/92) and 20% (18/92), respectively. The mortality rate at 30 days was significantly higher for patients who received inactive therapy (45% [5/11] ; table 2). Statistical significance was retained P = .0002 even after stratification for severity of illness and portal of entry. Specifically, of the 6 patients whose treatment with clindamycin clinically failed, 4 were infected with Bacteroides isolates resistant to clindamycin in vitro, whereas of the 13 patients who were clinically cured with clindamycin only 1 was infected with a clindamycin-resistant Bacteroides isolate ( ). P = .02 All 3 patients whose response to piperacillin therapy was clinical failure were infected with piperacillin-resistant Bacteroides strains, whereas none of the 4 patients who were clinically cured with piperacillin were infected with piperacillin-resistant Bacteroides (
). In addition, the response of the single P = .03 patient infected with a cefotetan-resistant strain who was treated with cefotetan was clinical failure.
Microbiological outcome. Seventy-five of 94 clinical assessments could also be evaluated for microbiological response. Eleven (15%) of 75 patients had persistence of Bacteroides in the blood (4 patients) or in the nonblood sites (7 patients), despite 3 days of antimicrobial therapy, and their response was considered microbiological persistence. Three (47%) of 7 patients who received inactive therapy had microbiological persistence, versus only 8 (12%) of 68 patients who received active therapy (  ; table 2 ). P = .06 The correlation of outcome with in vitro susceptibility was further demonstrated by assessment of the 8 patients who received an antianaerobic antimicrobial agent traditionally considered to be active in vitro (including clindamycin, piperacillin, and cefotetan). In vitro susceptibility testing established that the isolates were resistant to these agents (table 3) . Seven (89%) of these 8 patients had clinical failure. Of the 5 patients who had follow-up cultures performed, 4 (80%) of 5 had microbiological persistence manifested as bacteremia, despite 7, 8, 12, and 13 days of therapy. Five (71%) of seven patients who had clinical failure and 2 (50%) of 4 who had microbiological persistence died.
One of the 2 survivors had a pericolic abscess subsequent to an ileostomy revision procedure. Despite surgical drainage of the abscess and administration of clindamycin, this patient's bacteremia persisted for 12 days; the initial and subsequent blood isolates recovered during therapy were resistant to clindamycin. The bacteremia resolved after therapy was changed to metronidazole. The other surviving patient acquired bacteroides bacteremia from a wound infection and developed osteomyelitis of the foot. The diagnosis was made on the basis of radiologic findings in the foot, along with results of culture of a bone biopsy specimen. A course of cefotetan failed; there was persistent wound drainage, and culture of a drainage specimen was positive for Bacteroides; the isolate was resistant to cefotetan. Therapy was subsequently changed to clindamycin, and the infection resolved.
Early versus delayed therapy. For 54 patients, active therapy was started within 48 h of onset of bacteremia (early therapy). There was no significant difference in the rates of mortality, clinical outcome, or microbiological outcome between patients who received early therapy and patients who received delayed therapy.
Monotherapy versus combination therapy. Sixteen (19%) of 83 patients received combination therapy and 67 (81%) of 83 received monotherapy. The rates of mortality, clinical response, and microbiological response were not significantly different for the two groups: mortality rates were 12% (2/16) for patients who received combination therapy, and 15% (10/67) for patients who received monotherapy; clinical response rates were 25% (4/16) and 23% (15/67), respectively, and microbiological response rates were 21% (3/14) and 9% (6/55), respectively.
Risk factors for mortality. Univariate analyses revealed 2 factors associated with death: an APACHE score 115 (P = ) and receipt of inactive therapy ( ). Only an .0001 P = .03 APACHE score 115 was shown to be a risk factor for death in multivariate analyses ( ; tients received an antianaerobic antimicrobial agent before the onset of bacteremia: clindamycin (6 patients), ticarcillin/clavulanate (4 patients), piperacillin (3 patients), cefotetan (3 patients), and ampicillin/sulbactam (1 patient). The duration of prophylaxis or empirical therapy before the development of bacteremia ranged from 2 to 31 days (median, 7 days). Two of the 6 Bacteroides isolates recovered from patients who received clindamycin before the development of bacteremia were resistant to clindamycin in vitro. The mean duration of antimicrobial use before the occurrence of breakthrough bacteremia with an in vitro resistant isolate was 24 days (range, 17-31 days), whereas the mean duration of antimicrobial use before breakthrough infection with an in vitro susceptible isolate was 6 days (range, 2-13 days).
Two of the 3 isolates recovered from patients who received piperacillin prophylaxis and all 3 isolates recovered from those who received cefotetan prophylaxis were resistant in vitro to these agents. In contrast, none of the 5 isolates recovered from patients who received either ticarcillin/clavulanate or ampicillin/ sulbactam was resistant in vitro to these agents.
A significant association was found between in vitro resistance to piperacillin, cefoxitin, and cefotetan and the previous receipt of b-lactam antianaerobic agents (table 5) . Previous clindamycin therapy was not associated with resistance to b-lactam antianaerobic agents in vitro.
Discussion
To our knowledge, this is the first prospective study to demonstrate a correlation between in vitro susceptibility of antianaerobic antimicrobial agents and outcome for patients with bacteroides bacteremia. In this study, we asssessed outcome using 3 endpoints: mortality, clinical response, and microbiological response. We classified the clinical and microbiological response as cure or failure, and the microbiological response as eradication or persistence.
The mortality rate for patients who received therapy to which the Bacteroides blood isolate was resistant in vitro was significantly higher (45%) than the mortality rate for those who received therapy to which the isolate was susceptible in vitro (16%;
). The favorable impact of active therapy on out-P = .03 come was further supported by the clinical response: the rate of clinical failure was higher for patients who received inactive therapy (82%) than for patients who received active therapy (22%; ), a difference which remained significant even P = .0002 after stratification for severity of illness and portal of entry (table 2) .
The association between in vitro susceptibility results and improved outcome was also demonstrated by assessment of the outcome for the 8 patients who received empirical antimicrobial therapy believed to have activity against anaerobes, including clindamycin, piperacillin, and cefotetan. Isolates from these 8 patients were all resistant to these agents; 7 (89%) of the 8 were classified as clinical treatment failures and 5 (63%) of the 8 died.
The microbiological outcome was assessed for 75 patients NOTE. Data are proportion (%) of patients from whom resistant isolates were recovered. Breakpoints used were as follows: cefoxitin, 32 mg/mL; cefotetan, 32 mg/mL; piperacillin, 64 mg/mL; clindamycin, 4 mg/mL (see [9] ). NS, not significant.
a Of those who received antibiotics with anaerobic activity, 11 received a blactam, and 6 received clindamycin; 4 patient isolates were not tested. b One isolate could not be tested against clindamycin.
for whom follow-up culture findings were available. Similar to the clinical failure rate, the rate of microbiological failure (defined as persistence of Bacteroides in the blood or in a nonblood site despite 13 days of antimicrobial therapy and appropriate surgical drainage) was higher for patients who received inactive therapy (43%) than for patients who received active therapy (12%; ). P = . 056 We have shown that in vitro susceptibility testing of Bacteroides isolates reliably predicts patients' response to therapy: the specificity was 97% (65/67), and the positive predictive value was 82% (9/11). These results are excellent for a disease entity such as anaerobic infection, in which the outcome also depends on the treatment of other, coexistent infective bacteria, such as aerobic organisms. The sensitivity was relatively low, however (73%; 18/27); this underscores that in the determination of outcome, other important factors are the patient's immune status, severity of illness, adequacy of surgical drainage, and the residual focus of infections. We used breakpoints from an earlier NCCLS recommendation [9] .
The in vitro susceptibility testing method used in this study did not employ the media, inoculum, or breakpoints currently recommended by the NCCLS [12] . However, Bacteroides species grow well in many media, and the media and inoculum that we used have been in use for 120 years for testing anaerobic organisms [3, [13] [14] [15] . We and others have shown that there is a strong correlation between the in vitro results of different methods used to test for nonfastidious anaerobic organisms [5, 14, [16] [17] [18] .
The methods for anaerobic susceptibility testing recommended by the NCCLS have undergone a number of changes over the past 10 years [4, 9, 12] , and no clinical correlation has been found between NCCLS recommendations and clinical outcome [4] . In a retrospective analysis, we showed several media to have some correlation with clinical response [5] . Although our testing method used a lower inoculum and may have underestimated resistance rates, the results we did obtain support the conclusion that resistance among B. fragilis is associated with a worse outcome, as measured by clinical, microbiological, and survival endpoints.
In our study, 45% of the Bacteroides isolates were resistant to cefotetan, 37% to piperacillin, 16% to clindamycin, and 8% to cefoxitin. This trend of resistance paralleled the trends recently reported in the literature [6, 18, 19] and might be attributed to the widespread use of these antimicrobial agents. Our finding corroborates the hypothesis that Bacteroides isolates recovered from patients who had previously received antianaerobic b-lactam agents show a significantly higher rate of resistance to the b-lactam antibiotics than do isolates from patients who have not received such agents (table 5) .
In contrast to the b-lactam agents and clindamycin, no in vitro resistance to metronidazole and imipenem was demonstrated, and only rare resistance (!1%) to the b-lactam/b-lactamase inhibitor combinations such as ampicillin/sulbactam and ticarcillin/clavulanate was noted in Bacteroides species isolates. This finding suggests that these agents might be preferred for cases of bacteroides bacteremia in which the local or hospital in vitro susceptibility profiles are not known.
Unlike in vitro susceptibility testing of aerobic bacteria, in vitro susceptibility testing of anaerobic bacteria has not been widely used for clinical decision making. This has led to the false belief that resistance of anaerobes to antimicrobials is not important. However, we and others [3, 15, 19, 20] have shown that in vitro susceptibility testing of anaerobes is important for 3 reasons. First, similar to the experience with antimicrobial resistance of aerobes, it is well documented that antimicrobial resistance among Bacteroides species is increasing. Second, it has been demonstrated that there is significant disparity in the in vitro susceptibility patterns of anaerobes from different hospitals [18] ; therefore, pooled, multi-institutional susceptibility data cannot be extrapolated to individual hospitals. Third, in vitro resistance to a particular antimicrobial agent can be correlated with the failure to respond to therapy and with a poor clinical outcome.
These findings, taken together, suggest that in vitro susceptibility testing should be performed for Bacteroides isolates recovered from hospitalized patients with bacteremia, and such results should guide antimicrobial therapy. Given this clinical need, clinical laboratories may want to consider adoption of some easily adapted method for testing isolates. Clinicians also need to be vigilant about choosing the agents most active against anaerobic infections [19] .
